Prevalence of comorbidities in patients with type–2 diabetes mellitus. Issue 5 (October 2020)

• Record Type: Journal Article
• Authors: Akın, Seydahmet; Bölük, Cem
• Is Part Of: Primary care diabetes. Volume 14:Issue 5(2020)
• Page Start: 431
• Page End: 434
• Publication Date: 2020-10
• Subjects: Co-morbidity -- Diabetes mellitus -- Epidemiology -- Gender -- Insulin; Diabetes -- Periodicals; 616.462
• DOI: 10.1016/j.pcd.2019.12.006
• Languages: English
• ISSNs: 1751-9918

Abstract

Highlights: 98.5% of Turkish diabetic patients had at least one co-morbidity. The most common co-morbidities were hypertension and hyperlipidemia. Obesity and hyperlipidemia were more common in females. Diabetic nephropathy, coronary artery disease and stroke were more frequent in males. Abstract: Aims: The prevalence of diabetes mellitus is gradually increasing in Turkey and it is becoming a serious public health problem. Other diseases which accompany diabetes becloud its treatment and bring additional problems. Until now, there have been no studies investigating the prevalence of co-morbidities in Turkish diabetic patients. With this study, we aimed to resolve the deficiency on this subject. Methods: This cross-sectional descriptive epidemiological study was conducted between 2018 and 2019. Patients who had been regularly admitted to our diabetes center in the past 3 years were included in this study. Co-morbidities including hypertension, hyperlipidemia, obesity, coronary heart disease, cerebrovascular disease, diabetic retinopathy, and diabetic nephropathy were investigated. Factors relating to these co-morbidities were assessed. Results: After exclusion from analysis, 1024 patients were included in the study. The female/male ratio was found to be 1.7. The mean age of these patients was 69.3 ± 9.8. The mean diabetes duration was 22.2 ± 7.0. The most common co-morbidities were hypertension and hyperlipidemia by the rate of 84.9% and 65.6%. Obesity prevalence was 54.4%, nephropathy was 36.6%, coronary heart disease 22.8%, retinopathy 18.5% and stroke prevalence was found to be 4.8%. Age, diabetes duration and insulin usage were found to be significantly related to all co-morbidities. Conclusions: This study is significant in that it is the widest Turkish diabetic co-morbidity analysis study to date. When compared to other worldwide studies, co-morbidities were seen to be a little bit higher in Turkish diabetic patients. Clinicians need to not only focus on anti-diabetic treatment but also on other co-morbidities in terms of decreasing mortality and morbidity.